- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.67 Å
- Oligo State
- hetero-4-4-mer
- Ligands
- 4 x MTA: 5'-DEOXY-5'-METHYLTHIOADENOSINE(Non-covalent)
- 4 x 01: [2-(cyclobutylamino)pyridin-4-yl][(3R,4R)-3-hydroxy-4-{6-[(1-methyl-1H-pyrazol-5-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl}piperidin-1-yl]methanone
01.2: 25 residues within 4Å:- Chain A: F.308, Y.312, Q.317, L.320, L.327, Y.332, F.335, E.336, K.341, Y.342, A.374, G.375, R.376, P.378, E.443, L.445, G.446, S.447, E.452, V.511, F.585, S.586, W.587, F.588
- Ligands: MTA.1
17 PLIP interactions:17 interactions with chain A- Hydrophobic interactions: A:Y.312, A:L.320, A:L.327, A:F.335, A:F.335, A:F.335, A:F.335, A:P.378, A:V.511, A:F.585, A:F.588
- Hydrogen bonds: A:R.376, A:F.585, A:W.587, A:F.588
- Salt bridges: A:E.452
- pi-Cation interactions: A:F.335
01.26: 25 residues within 4Å:- Chain C: F.308, Y.312, Q.317, L.320, L.327, Y.332, F.335, E.336, K.341, Y.342, A.374, G.375, R.376, P.378, E.443, L.445, G.446, S.447, E.452, V.511, F.585, S.586, W.587, F.588
- Ligands: MTA.25
17 PLIP interactions:17 interactions with chain C- Hydrophobic interactions: C:Y.312, C:L.320, C:L.327, C:F.335, C:F.335, C:F.335, C:F.335, C:P.378, C:V.511, C:F.585, C:F.588
- Hydrogen bonds: C:R.376, C:F.585, C:W.587, C:F.588
- Salt bridges: C:E.452
- pi-Cation interactions: C:F.335
01.50: 25 residues within 4Å:- Chain E: F.308, Y.312, Q.317, L.320, L.327, Y.332, F.335, E.336, K.341, Y.342, A.374, G.375, R.376, P.378, E.443, L.445, G.446, S.447, E.452, V.511, F.585, S.586, W.587, F.588
- Ligands: MTA.49
17 PLIP interactions:17 interactions with chain E- Hydrophobic interactions: E:Y.312, E:L.320, E:L.327, E:F.335, E:F.335, E:F.335, E:F.335, E:P.378, E:V.511, E:F.585, E:F.588
- Hydrogen bonds: E:R.376, E:F.585, E:W.587, E:F.588
- Salt bridges: E:E.452
- pi-Cation interactions: E:F.335
01.74: 25 residues within 4Å:- Chain G: F.308, Y.312, Q.317, L.320, L.327, Y.332, F.335, E.336, K.341, Y.342, A.374, G.375, R.376, P.378, E.443, L.445, G.446, S.447, E.452, V.511, F.585, S.586, W.587, F.588
- Ligands: MTA.73
17 PLIP interactions:17 interactions with chain G- Hydrophobic interactions: G:Y.312, G:L.320, G:L.327, G:F.335, G:F.335, G:F.335, G:F.335, G:P.378, G:V.511, G:F.585, G:F.588
- Hydrogen bonds: G:R.376, G:F.585, G:W.587, G:F.588
- Salt bridges: G:E.452
- pi-Cation interactions: G:F.335
- 64 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.3: 7 residues within 4Å:- Chain A: E.137, D.138, N.139, T.140, N.199, L.203
- Chain C: T.626
Ligand excluded by PLIPEDO.4: 4 residues within 4Å:- Chain A: Y.543, C.544, T.545
- Chain C: R.108
Ligand excluded by PLIPEDO.5: 6 residues within 4Å:- Chain A: K.103, V.104, E.105, R.108
- Chain B: Y.221, N.242
Ligand excluded by PLIPEDO.6: 7 residues within 4Å:- Chain A: N.541, R.542, W.611, R.612, C.613
- Chain C: E.112, R.144
Ligand excluded by PLIPEDO.7: 4 residues within 4Å:- Chain A: L.323, K.401, D.427, L.645
Ligand excluded by PLIPEDO.8: 8 residues within 4Å:- Chain A: W.194, D.227, R.228, L.230, S.484, H.518, N.553, T.554
Ligand excluded by PLIPEDO.9: 8 residues within 4Å:- Chain G: L.119, G.122, A.123, L.127, F.130, H.149, S.157, F.159
Ligand excluded by PLIPEDO.10: 1 residues within 4Å:- Chain A: E.475
Ligand excluded by PLIPEDO.11: 5 residues within 4Å:- Chain A: F.54, Q.117, F.121
- Chain G: P.403, V.407
Ligand excluded by PLIPEDO.12: 6 residues within 4Å:- Chain A: P.233, I.234, K.235, L.268, K.487, N.516
Ligand excluded by PLIPEDO.13: 8 residues within 4Å:- Chain A: S.329, Q.330, E.333, R.376
- Chain G: D.78, L.81, G.83, W.86
Ligand excluded by PLIPEDO.14: 3 residues within 4Å:- Chain A: Q.317, S.318, C.495
Ligand excluded by PLIPEDO.15: 3 residues within 4Å:- Chain A: T.545, R.609
- Chain C: D.138
Ligand excluded by PLIPEDO.16: 6 residues within 4Å:- Chain A: E.105, R.108, R.109, E.112
- Chain C: R.542, Y.543
Ligand excluded by PLIPEDO.23: 4 residues within 4Å:- Chain A: N.135
- Chain B: K.153, A.176, Q.177
Ligand excluded by PLIPEDO.24: 4 residues within 4Å:- Chain B: K.126, F.127, C.128, K.129
Ligand excluded by PLIPEDO.27: 7 residues within 4Å:- Chain A: T.626
- Chain C: E.137, D.138, N.139, T.140, N.199, L.203
Ligand excluded by PLIPEDO.28: 4 residues within 4Å:- Chain A: R.108
- Chain C: Y.543, C.544, T.545
Ligand excluded by PLIPEDO.29: 6 residues within 4Å:- Chain C: K.103, V.104, E.105, R.108
- Chain D: Y.221, N.242
Ligand excluded by PLIPEDO.30: 7 residues within 4Å:- Chain A: E.112, R.144
- Chain C: N.541, R.542, W.611, R.612, C.613
Ligand excluded by PLIPEDO.31: 4 residues within 4Å:- Chain C: L.323, K.401, D.427, L.645
Ligand excluded by PLIPEDO.32: 8 residues within 4Å:- Chain C: W.194, D.227, R.228, L.230, S.484, H.518, N.553, T.554
Ligand excluded by PLIPEDO.33: 8 residues within 4Å:- Chain E: L.119, G.122, A.123, L.127, F.130, H.149, S.157, F.159
Ligand excluded by PLIPEDO.34: 1 residues within 4Å:- Chain C: E.475
Ligand excluded by PLIPEDO.35: 5 residues within 4Å:- Chain C: F.54, Q.117, F.121
- Chain E: P.403, V.407
Ligand excluded by PLIPEDO.36: 6 residues within 4Å:- Chain C: P.233, I.234, K.235, L.268, K.487, N.516
Ligand excluded by PLIPEDO.37: 8 residues within 4Å:- Chain C: S.329, Q.330, E.333, R.376
- Chain E: D.78, L.81, G.83, W.86
Ligand excluded by PLIPEDO.38: 3 residues within 4Å:- Chain C: Q.317, S.318, C.495
Ligand excluded by PLIPEDO.39: 3 residues within 4Å:- Chain A: D.138
- Chain C: T.545, R.609
Ligand excluded by PLIPEDO.40: 6 residues within 4Å:- Chain A: R.542, Y.543
- Chain C: E.105, R.108, R.109, E.112
Ligand excluded by PLIPEDO.47: 4 residues within 4Å:- Chain C: N.135
- Chain D: K.153, A.176, Q.177
Ligand excluded by PLIPEDO.48: 4 residues within 4Å:- Chain D: K.126, F.127, C.128, K.129
Ligand excluded by PLIPEDO.51: 7 residues within 4Å:- Chain E: E.137, D.138, N.139, T.140, N.199, L.203
- Chain G: T.626
Ligand excluded by PLIPEDO.52: 4 residues within 4Å:- Chain E: Y.543, C.544, T.545
- Chain G: R.108
Ligand excluded by PLIPEDO.53: 6 residues within 4Å:- Chain E: K.103, V.104, E.105, R.108
- Chain F: Y.221, N.242
Ligand excluded by PLIPEDO.54: 7 residues within 4Å:- Chain E: N.541, R.542, W.611, R.612, C.613
- Chain G: E.112, R.144
Ligand excluded by PLIPEDO.55: 4 residues within 4Å:- Chain E: L.323, K.401, D.427, L.645
Ligand excluded by PLIPEDO.56: 8 residues within 4Å:- Chain E: W.194, D.227, R.228, L.230, S.484, H.518, N.553, T.554
Ligand excluded by PLIPEDO.57: 8 residues within 4Å:- Chain C: L.119, G.122, A.123, L.127, F.130, H.149, S.157, F.159
Ligand excluded by PLIPEDO.58: 1 residues within 4Å:- Chain E: E.475
Ligand excluded by PLIPEDO.59: 5 residues within 4Å:- Chain C: P.403, V.407
- Chain E: F.54, Q.117, F.121
Ligand excluded by PLIPEDO.60: 6 residues within 4Å:- Chain E: P.233, I.234, K.235, L.268, K.487, N.516
Ligand excluded by PLIPEDO.61: 8 residues within 4Å:- Chain C: D.78, L.81, G.83, W.86
- Chain E: S.329, Q.330, E.333, R.376
Ligand excluded by PLIPEDO.62: 3 residues within 4Å:- Chain E: Q.317, S.318, C.495
Ligand excluded by PLIPEDO.63: 3 residues within 4Å:- Chain E: T.545, R.609
- Chain G: D.138
Ligand excluded by PLIPEDO.64: 6 residues within 4Å:- Chain E: E.105, R.108, R.109, E.112
- Chain G: R.542, Y.543
Ligand excluded by PLIPEDO.71: 4 residues within 4Å:- Chain E: N.135
- Chain F: K.153, A.176, Q.177
Ligand excluded by PLIPEDO.72: 4 residues within 4Å:- Chain F: K.126, F.127, C.128, K.129
Ligand excluded by PLIPEDO.75: 7 residues within 4Å:- Chain E: T.626
- Chain G: E.137, D.138, N.139, T.140, N.199, L.203
Ligand excluded by PLIPEDO.76: 4 residues within 4Å:- Chain E: R.108
- Chain G: Y.543, C.544, T.545
Ligand excluded by PLIPEDO.77: 6 residues within 4Å:- Chain G: K.103, V.104, E.105, R.108
- Chain H: Y.221, N.242
Ligand excluded by PLIPEDO.78: 7 residues within 4Å:- Chain E: E.112, R.144
- Chain G: N.541, R.542, W.611, R.612, C.613
Ligand excluded by PLIPEDO.79: 4 residues within 4Å:- Chain G: L.323, K.401, D.427, L.645
Ligand excluded by PLIPEDO.80: 8 residues within 4Å:- Chain G: W.194, D.227, R.228, L.230, S.484, H.518, N.553, T.554
Ligand excluded by PLIPEDO.81: 8 residues within 4Å:- Chain A: L.119, G.122, A.123, L.127, F.130, H.149, S.157, F.159
Ligand excluded by PLIPEDO.82: 1 residues within 4Å:- Chain G: E.475
Ligand excluded by PLIPEDO.83: 5 residues within 4Å:- Chain A: P.403, V.407
- Chain G: F.54, Q.117, F.121
Ligand excluded by PLIPEDO.84: 6 residues within 4Å:- Chain G: P.233, I.234, K.235, L.268, K.487, N.516
Ligand excluded by PLIPEDO.85: 8 residues within 4Å:- Chain A: D.78, L.81, G.83, W.86
- Chain G: S.329, Q.330, E.333, R.376
Ligand excluded by PLIPEDO.86: 3 residues within 4Å:- Chain G: Q.317, S.318, C.495
Ligand excluded by PLIPEDO.87: 3 residues within 4Å:- Chain E: D.138
- Chain G: T.545, R.609
Ligand excluded by PLIPEDO.88: 6 residues within 4Å:- Chain E: R.542, Y.543
- Chain G: E.105, R.108, R.109, E.112
Ligand excluded by PLIPEDO.95: 4 residues within 4Å:- Chain G: N.135
- Chain H: K.153, A.176, Q.177
Ligand excluded by PLIPEDO.96: 4 residues within 4Å:- Chain H: K.126, F.127, C.128, K.129
Ligand excluded by PLIP- 16 x NA: SODIUM ION(Non-functional Binders)
NA.17: 2 residues within 4Å:- Chain A: Y.489, Q.596
Ligand excluded by PLIPNA.18: 1 residues within 4Å:- Chain A: Q.271
Ligand excluded by PLIPNA.19: 1 residues within 4Å:- Chain A: T.637
Ligand excluded by PLIPNA.20: 1 residues within 4Å:- Chain A: T.642
Ligand excluded by PLIPNA.41: 2 residues within 4Å:- Chain C: Y.489, Q.596
Ligand excluded by PLIPNA.42: 1 residues within 4Å:- Chain C: Q.271
Ligand excluded by PLIPNA.43: 1 residues within 4Å:- Chain C: T.637
Ligand excluded by PLIPNA.44: 1 residues within 4Å:- Chain C: T.642
Ligand excluded by PLIPNA.65: 2 residues within 4Å:- Chain E: Y.489, Q.596
Ligand excluded by PLIPNA.66: 1 residues within 4Å:- Chain E: Q.271
Ligand excluded by PLIPNA.67: 1 residues within 4Å:- Chain E: T.637
Ligand excluded by PLIPNA.68: 1 residues within 4Å:- Chain E: T.642
Ligand excluded by PLIPNA.89: 2 residues within 4Å:- Chain G: Y.489, Q.596
Ligand excluded by PLIPNA.90: 1 residues within 4Å:- Chain G: Q.271
Ligand excluded by PLIPNA.91: 1 residues within 4Å:- Chain G: T.637
Ligand excluded by PLIPNA.92: 1 residues within 4Å:- Chain G: T.642
Ligand excluded by PLIP- 4 x GOL: GLYCEROL(Non-functional Binders)
GOL.21: 4 residues within 4Å:- Chain A: I.150, H.154, S.207, R.209
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:S.207, A:R.209, A:R.209
GOL.45: 4 residues within 4Å:- Chain C: I.150, H.154, S.207, R.209
3 PLIP interactions:3 interactions with chain C- Hydrogen bonds: C:S.207, C:R.209, C:R.209
GOL.69: 4 residues within 4Å:- Chain E: I.150, H.154, S.207, R.209
3 PLIP interactions:3 interactions with chain E- Hydrogen bonds: E:S.207, E:R.209, E:R.209
GOL.93: 4 residues within 4Å:- Chain G: I.150, H.154, S.207, R.209
3 PLIP interactions:3 interactions with chain G- Hydrogen bonds: G:S.207, G:R.209, G:R.209
- 4 x CL: CHLORIDE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cottrell, K.M. et al., MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design. J.Med.Chem. (2025)
- Release Date
- 2025-03-05
- Peptides
- Protein arginine N-methyltransferase 5: ACEG
Methylosome protein 50: BDFH - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
AE
AG
AB
BD
BF
BH
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.67 Å
- Oligo State
- hetero-4-4-mer
- Ligands
- 4 x MTA: 5'-DEOXY-5'-METHYLTHIOADENOSINE(Non-covalent)
- 4 x 01: [2-(cyclobutylamino)pyridin-4-yl][(3R,4R)-3-hydroxy-4-{6-[(1-methyl-1H-pyrazol-5-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl}piperidin-1-yl]methanone
- 64 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- 16 x NA: SODIUM ION(Non-functional Binders)
- 4 x GOL: GLYCEROL(Non-functional Binders)
- 4 x CL: CHLORIDE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cottrell, K.M. et al., MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design. J.Med.Chem. (2025)
- Release Date
- 2025-03-05
- Peptides
- Protein arginine N-methyltransferase 5: ACEG
Methylosome protein 50: BDFH - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
AE
AG
AB
BD
BF
BH
B